Browse by author
Lookup NU author(s): Dr Supriyo Choudhury, Professor Mark BakerORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Since its introduction as a treatment for strabismus, botulinum toxin (BoNT) has had a phenomenal journey and is now recommended as first-line treatment for focal dystonia, despite short-term clinical benefits and the risks of adverse effects. To cater for the high demand across various medical specialties, at least six US Food and Drug Administration (FDA)-approved formulations of BoNT are currently available for diverse labelled indications. The toxo-pharmacological properties of these formulations are not uniform and thus should not be used interchangeably. Synthetic BoNTs and BoNTs from non-clostridial sources are not far from clinical use. Moreover, the study of mutations in naturally occurring toxins has led to modulation in the toxo-pharmacokinetic properties of BoNTs, including the duration and potency. We present an overview of the toxo-pharmacology of conventional and novel BoNT preparations, including those awaiting imminent translation from the laboratory to the clinic.
Author(s): Choudhury S, Baker MR, Chatterjee S, Kumar H
Publication type: Review
Publication status: Published
Journal: Toxins
Year: 2021
Volume: 13
Issue: 1
Print publication date: 14/01/2021
Online publication date: 14/01/2021
Acceptance date: 08/01/2021
ISSN (electronic): 2072-6651
Publisher: NLM (Medline)
URL: https://doi.org/10.3390/toxins13010058
DOI: 10.3390/toxins13010058
PubMed id: 33466571
Data Access Statement: Not applicable.
